Cadrenal Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CVKD Nasdaq 2836 www.cadrenal.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - May 19th, 2026 2:30 pm
CVKD: Designing Phase 3 Trial for CAD-1005 in HIT - May 8th, 2026 6:15 am
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA - May 7th, 2026 6:30 am
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) - Apr 30th, 2026 6:30 am
Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program - Apr 20th, 2026 8:47 pm
CVKD: Results Show 12-LOX Inhibition Targets Inflammation from Obesity and Type 2 Diabetes - Apr 8th, 2026 6:19 am
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting - Mar 31st, 2026 6:45 am
OTC Markets Hosts Virtual Investor Presentation with Quang Pham, Chairman and CEO of Cadrenal Therapeutics, and David Bautz, PhD, Senior Analyst at Zacks SCR - Mar 20th, 2026 10:21 am
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Mar 13th, 2026 6:35 am
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes - Mar 12th, 2026 6:00 am
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th - Mar 10th, 2026 8:21 am
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - Mar 2nd, 2026 6:00 am
CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events - Feb 25th, 2026 4:38 am
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement - Feb 24th, 2026 6:30 am
CVKD: Acquires 12-LOX Inhibitor for the Treatment of Heparin-Induced Thrombocytopenia (HIT) - Feb 20th, 2026 4:05 am
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor - Jan 12th, 2026 6:00 am
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - Dec 30th, 2025 6:00 am
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On - Dec 29th, 2025 6:00 am
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 - Dec 17th, 2025 7:00 am
Cadrenal's Quiet Expansion Play Is Starting to Get Loud - Dec 12th, 2025 9:00 am